Lung cancer biopsy dislodges tumor cells into circulating blood

Noriyoshi Sawabata, Tomotaka Kitamura, Yuko Nitta, Tomoyo Taketa, Takeshi Ohno, Tatsuya Fukumori, Takeru Hyakutake, Takahito Nakamura

Division of General Thoracic Surgery, Respiratory Center, Hoshigaoka Medical Center, Hirakata, Osaka 574-8511, Japan.

Correspondence to: Dr. Noriyoshi Sawabata, Division of General Thoracic Surgery, Respiratory Center, Hoshigaoka Medical Center, 4-8-1 Hoshigaoka, Hirakata, Osaka 574-8511, Japan. E-mail: nsawabata@hotmail.com


Aim: A “seed” of lung cancer metastasis is circulating tumor cells (CTCs), which may be dislodged from a tumor during biopsy. This possibility was assessed among patients who underwent lung tumor biopsy using flexible fiber-topic bronchoscopy (FFB).

Methods: The study involved six patients with non-small cell lung cancer who underwent FFB biopsy to diagnose a lesion pathologically (5 males and 1 female, median age 63 years, 6 adenocarcinomas, of 4 clinical-stage IA, 1 stage IB, and 1 stage IIIA), CTCs were extracted from the peripheral vein blood at pre-FFB and at post-FFB using a size selection method.

Results: No tumor cell was detected at pre- and post-FFB was in three cases (50%); no tumor cells were detected pre-FFB while CTCs were detected at post-FFB in two cases (33.3%); and CTCs were detected at pre-FFB with numerous CTCs detected at post-FFB in one case (17.7%). In addition, similar tendencies were observed in each analysis of single-cell and clustered-cell categories.

Conclusion: These results suggest that a FFB biopsy of lung cancer may potentially dislodge CTCs from a tumor into the circulating peripheral blood.

Key words: Lung cancer, biopsy, circulating tumor cells

INTRODUCTION

There are three principal methods to diagnose a pulmonary lung cancer region pathologically. One is trans-bronchial biopsy (TBB) using flexible fiber-topic bronchoscopy (FFB) and others are computed tomography (CT), guided fine needle aspiration biopsy (FNAC), and surgical resection.[1] Each method is effective but has some weak points.

First, FNAC has the potential to disseminate cancer cells through the needle tract.[2] According to a study using extracted human lung lobe with cancer lesions, cancer cells were detected at a rate of 10% in the saline used to wash the pulmonary lobe surface. This rate increased to 60% after FNAC.[2] In a clinical setting, it has been reported that the rate of relapse (pleural recurrence) was higher in an FNAC group than in a control group among surgical lung cancer cases.[3,4] In addition, there has been a recommendation use caution in employing FNAC as a method of lung cancer diagnosis based on evidence.[5]
Pulmonary wedge resection is also a crucial diagnostic technique for pulmonary nodules that may indicate lung cancer. This procedure also may potentially dislodge tumor cells from the surgical margin to the body, even when a specimen of pulmonary wedge resection contents histologically malignant negative surgical margin.\[6,7\] Malignant-positive results in the surgical margin have been reported to be an indicator of poor prognosis in a retrospective study.\[8\] Furthermore, it has been reported that malignant surgical margins of pulmonary wedge resection for lung cancer was a negative prognostic predictor in a subset analysis included in a multicenter prospective study of limited pulmonary resection for compromised lung cancer patients.\[9\]

TBB is also an important method in diagnosing lung cancer. However, there have been reports demonstrating a prognostic disadvantage for biopsy using FFB.\[10,11\] An observational study revealed that patients who were diagnosed with lung cancer using a trans-pleural technique had a statistically ($P = 0.04$) better 5-year survival rate than patients diagnosed using TBB.\[10\] This phenomenon was also reported in a study using propensity score matched analysis.\[11\] These results may mean that an intervention in a cancer lesion using TBB may dislodge cancer cells from the lesion to the circulating blood.

There are also studies revealing that manipulation during lung cancer surgery has the potential to dislodge cancer cells into the circulating blood, which is reported to be a prognostic indicator of poor outcomes.\[12-15\] Above all, detecting cluster circulating tumor cell (CTC) is speculated the best a strong predictor of early recurrence.\[13\] FBB also manipulates the area of lung cancer during biopsy; thus, CTCs might be dislodged from the lesion to the circulating blood as the same manner as surgical manipulation. For that reason we assessed the status of CTC before and after FFB biopsy to diagnose lung cancer.

**METHODS**

This investigation was approved by the institutional review board of the Hoshigaoka Medical Center and all patients provided their informed consent to participate in this study.

Among 6 patients with non-small cell lung cancer (NSCLC) who underwent FFB to diagnose a lesion pathologically, CTCs were extracted from a peripheral vein at pre-FFB and at post-FFB using a size selection method [ScreenCell® Cyto (ScreenCell, Westford, MA)]; using a micro-pore film that extracts formalin-fixed tumor cells.\[16\] ScreenCell® Cyto is designed for cytological studies and the filter allows a fast and regular filtration, preserving the CTC morphology and microcluster structures. Blood samples were diluted with the (LC/CC) ScreenCell® (ScreenCell, Westford, MA) dilution buffers for fixed cells. At the end of filtration, the ScreenCell® Cyto filter was released onto a standard microscopy glass slide; a 7 mm circular coverslip was then laid down on the filter with the appropriate mounting medium.

Peripheral blood (3 mL) was collected into an EDTA tube pre- and post-FFB. Tumor cells in two blood samples from each patient were simultaneously extracted using the method. These extracted cells were stained using a hematoxylin and eosin method and observed with a conventional microscope. Tumor cells were classified using three categories: no tumor cells detected (N), single cell or less than four cells (S), and clustered cells (C).

**RESULTS**

FFB-TBB was carried out under localized anesthesia using radiography to confirm that a sampling device reaches hits at a lesion. Samples for cytology and pathology were collected from a lesion. Cytological diagnosis of malignancy was achieved in only four cases, while all lesions revealed a pathological diagnosis, which is the result of manipulation that FFB-TBB made while contacting a cancer lesion. There was no complication during and after FFB-TBB and all patients were discharged without event.

Patient/tumor characteristics and status of CTC in each patient are shown in Table 1. There were five males and one female with a median age of 63 years, (range 59-78 years). According to CT findings, all lesions were solid and tumor size on CT findings was a median 2.5 cm (range 2.1-3.5 cm). Tumor invasiveness status in pathological diagnosis was “invasive” in all cases. Clinical stage was clinical -- stage IA in four cases, stage IB in one case and stage IIIA in one case. Singular or cluster CTCs were detectable as shown in Figure 1. The CTC counts at pre- and post-FFB procedures are shown in Table 1. In one case CTC was detectable before FFB. This case was stage IIIA with mediastinal lymphadenopathy. In an analysis of all cell categories, no tumor cell was detected at pre-FFB; at post-FFB a tumor cell was detected in three cases (50.0%). No tumor cell was detected at pre-FFB, while CTCs were detected at post-FFB in two cases (33.3%) and CTCs were detected at pre-FFB, while numerous CTCs were detected at post-FFB in one case (17.7%). In analysis of singular cells, no tumor...
cell was detected at pre-FFB, while in three cases cells were detected at post-FFB (50.0%). No tumor cell was detected at pre-FFB while some CTCs were detected at post-FFB in two cases (33.3%) while some CTCs were detected at pre-FFB. Numerous CTCs were detected at post-FFB in five cases (63.3%), with some CTCs being detected at pre-FFB and many CTCs detected at post-FFB in one case (17.7%). The alterations of CTC counts are graphically demonstrated in Figure 2.

**DISCUSSION**

In our assessment of CTCs at pre-FFB and at post-FFB biopsy, the amount of CTC is not decreased after an FFB procedure, and in cases involving CTCs the count of CTCs increased at post-FFB. These results suggest that a tumor biopsy of a lung cancer lesion has the potential to dislodge tumor cells into the peripheral circulating blood, as can occur with a surgical procedure.\(^{[12-15]}\)

Initially, tumor cell dislodgement to the peripheral circulating blood by surgical manipulation was demonstrated using a cytological technique, but the sensitivity was very low.\(^{[17]}\) Later, polymerase chain reaction\(^{[18,19]}\) and flow-cytometry\(^{[20]}\) methods were introduced to improve sensitivity and specificity, but results were not predictable. Morphological detection of CTC dislodgement was shown using the EpCAM positive selection method [CellSearch\textsuperscript{®} system (Janssen Diagnostics, Raritan, NJ)], but the sensitivity was still low.\(^{[15]}\) As such, isolated tumor cells (ITC), surrogates of CTC, were extracted from pulmonary vein blood, revealing that detecting ITC/CTC was an indicator of early recurrence; the presence of cluster ITC/CTC indicated wrong prognosis, using the EpCAM positive selection method\(^{[21]}\) or the CD45 negative depression gravity method [RosettSep\textsuperscript{®} (Stemcell Technologies, Vancouver, Canada)].\(^{[22-24]}\) As the sensitivity of such CTC detecting methods was not greater, the sample used pulmonary vein blood, because it contains more ITC/CTC than the peripheral circulating blood.\(^{[24]}\)

Size selection methods [ISET\textsuperscript{®} (Rarecells Diagnostics, Paris, France) and ScreenCell\textsuperscript{®} Cyto] are highly sensitive for cluster CTC, and therefore the sampling of CTC extraction using size selection methods can use peripheral blood.\(^{[16,29]}\) Recently, CTC dislodgement during surgery for lung cancer was proven by detecting CTCs in the peripheral circulating blood using a size selection method, and the presence of cluster CTC has been an indicator of early recurrence among surgical lung cancer patients.\(^{[13]}\)

A CTC assessment during FFB procedures needs a method that can extract CTCs from the peripheral blood sensitively, and for this reason we chose the sensitive

**Table 1: Patient/tumor characteristics and status of CTC**

<table>
<thead>
<tr>
<th>No.</th>
<th>Age</th>
<th>Gender</th>
<th>Type</th>
<th>Size (cm)</th>
<th>Tumor histology</th>
<th>Stage</th>
<th>Status of CTC</th>
<th>All CTC categories</th>
<th>Singular CTC</th>
<th>Cluster CTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65</td>
<td>M</td>
<td>Pure solid</td>
<td>2.1</td>
<td>Invasive AD</td>
<td>IA</td>
<td>1b</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>64</td>
<td>M</td>
<td>Pure solid</td>
<td>2.5</td>
<td>Invasive AD</td>
<td>IA</td>
<td>1b</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>78</td>
<td>M</td>
<td>Pure solid</td>
<td>2.9</td>
<td>Invasive AD</td>
<td>IA</td>
<td>1b</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>63</td>
<td>M</td>
<td>Pure solid</td>
<td>2.4</td>
<td>Invasive AD</td>
<td>IIa</td>
<td>1b</td>
<td>2</td>
<td>17</td>
<td>37</td>
</tr>
<tr>
<td>5</td>
<td>59</td>
<td>F</td>
<td>Pure solid</td>
<td>3.5</td>
<td>Invasive AD</td>
<td>IB</td>
<td>2a</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>62</td>
<td>M</td>
<td>Pure solid</td>
<td>2.8</td>
<td>Invasive AD</td>
<td>IA</td>
<td>1b</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

CT: computed tomography; CTC: circulating tumor cell; M: male; F: female; AD: adenocarcinoma; C: clinical; T: tumor; N: node
method of micropore membrane size selection. This let us that the FFB procedure causes CTCs dislodgement into the circulating blood, with distinguishing cluster CTC that may be a crucial indicator of tumorigenesis.[26]

In addition to tumor cell dissemination into the circulating blood by surgical manipulation and TBB, the pleural cavity and the surgical margin are other areas where cancer cells can be disseminated by interventions such as FNAC and pulmonary wedge resection. Sawabata et al.[2] demonstrated cancer cell dissemination from a lung cancer lesion through the needle tract at the visceral pleura. This phenomenon may support the high rates of relapse as pleural carcinomatosis in surgical patients with lung cancer who undergo FNAC.[3,4] In cases of pulmonary wedge resection of lung cancer, malignant positive margin detected by cytology is an indicator of recurrence and poor survival,[6] while attaining a malignant-negative margin of pulmonary wedge lung cancer resection is speculated to be an indicator of good prognosis. Altorki et al.[27] reported a prognosis of pulmonary wedge lung cancer resection similar to that of segmentectomy when a wedge resection was carried out with sufficient margin distance and malignant-negative surgical margin.

In addition to surgical margin dissemination, residual lung lobe is another area where tumor cells are disseminated during pulmonary wedge lung cancer resection.[28] The possibility of tumor cells in the residual lung lobe parenchyma is related to the margin distance from a cancer to the margin of the pulmonary wedge resection, and a detection of clustered tumor cells is an indicator of early recurrence.[28] These observations in FNAC and surgery suggest that the importance of controlling cancer cell dissemination is as great in those settings as in TBB.

Although this study has the limitation of a relatively small patient population, results using the size selection method revealed an increased number of both singular and cluster CTC post-FFB biopsy, therefore, further investigation into the implications of such CTCs is recommended.

Acknowledgments
The authors thank Dr. Hiroshi Maruyama and Dr. Yuko Torii (Department of Pathology, Hoshigaoka Medical Center) for their contributions to the pathological diagnoses.

Financial support and sponsorship
This research was supported by a Grant-in-Aid for Scientific Research [(B) 25293301] from the Japan Ministry of Education, Science, Sports and Culture.

Conflicts of interest
There are no conflicts of interest.

Patient consent
All patients provided their informed consent to participate in this study.
Ethics approval
This investigation was approved by the institutional review board of the Hoshigaoka Medical Center (No. 1412) in April 4, 2014.

REFERENCES